Publication: Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome (review)
Issued Date
2008-10-01
Resource Type
ISSN
1021335X
Other identifier(s)
2-s2.0-54949099986
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Oncology Reports. Vol.20, No.4 (2008), 699-703
Suggested Citation
Suebwong Chuthapisith, Jennifer M. Eremin, Oleg Eremin Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome (review). Oncology Reports. Vol.20, No.4 (2008), 699-703. doi:10.3892/or_00000062 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18853
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome (review)
Other Contributor(s)
Abstract
The ability to predict the response to neoadjuvant chemotherapy (NAC) prior to or shortly after commencing treatment, in women with large or locally advanced breast cancers, would not only prevent patients from experiencing unnecessary drug morbidity but also reduce the high cost associated with drug usage and utilisation of resources with NAC. Ability to estimate residual cancer volume after NAC is of clinical relevance to subsequent therapeutic surgical options. Various approaches, using conventional histopathological characteristics and imaging modalities to evaluate and predict the response to NAC, have not been able to provide accurate and reliable data. Novel biomolecular imaging, new biomarkers and recent cancer genomic and proteomic profiling, introduced into clinical practice, have produced preliminary promising results. We describe and discuss these molecular characteristics and approaches and their applications to NAC in breast cancer management.